In addition, we aimed to study the relationship between the level of CHI3L1 in CSF and the clinical disability parameters in MS, including cognitive impairment with the aim of determining whether CHI3L1 could be used as a biomarker for MS progression. The gene discussed is CHI3L1; the disease is myeloid sarcoma.